Restore Vision Inc., a clinical-stage biotechnology company advancing gene therapies for retinal disorders, today announced that the first patient in its Phase I/II clinical trial with RV-001 has been ...

If a company chooses to publish the data, it's usually once a year in their Annual Report. All data is manually compiled so there might be a delay between the Annual Report being published and the ...

Chimeric Therapeutics (ASX:CHM) has announced that the University of Chicago Medicine is now open to enrolling patients in the Phase 1/2 multi-centre ...